Five years later, GSK's Benlysta wins backing from NICE

GSK

GlaxoSmithKline lupus drug Benlysta first won European approval nearly 5 years ago--but it’s just now getting a thumbs-up from England’s cost watchdogs.

After several years of rejecting the drug on the grounds that its value didn’t justify its price, the National Institute of Health and Care Excellence released guidance Tuesday recommending the NHS adopt the Glaxo product.

Of course, there are some conditions. GSK will be offering up the drug at a discounted price, and NICE also stipulated that clinical data on Benlysta’s use should be collected to clear up any lingering questions about the product’s efficacy.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Glaxo is no stranger to price negotiations in its home country. In 2014, NICE demanded another discount--or so-called “patient-access scheme” in exchange for a recommendation on Tafinlar, a melanoma drug that ultimately went to Novartis in the companies’ multibillion-dollar asset swap. The pharma giant had work to do after that transaction closed, too, haggling its way onto the U.K.’s list of routine vaccinations for babies with meningitis B shot Bexsero.  

But things took much longer with Benlysta, a med it acquired full rights to with its $3 billion takeover of Human Genome Sciences. Back in 2012, after nixing the med--which ran about $3,700 over the first four weeks and then $1,227 every four weeks--NICE gatekeepers upheld an appeal from the company, agreeing to once again review if Benlysta was worth it. It opened a second public consultation in July 2013.

This time around, the positive opinion will result in a boost for Glaxo’s pharma unit, which has recently been battered by a payer squeeze on lead product Advair.

- read the guidance (PDF)

Special Report: The top 15 pharma companies by 2014 revenue - GlaxoSmithKline

Related Articles:
GSK execs, analysts talk up a turnaround as Q1 sales, profits beat estimates
With MenB vaccine Bexsero in hand, GSK aims for a price deal in England
NICE says 'yes' to GSK's melanoma pill, but only with a price cut
GlaxoSmithKline aims to pump up Benlysta with new vasculitis use
GSK's Benlysta gets another shot at U.K. market

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.